<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v =2.1 7.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff =20230831000934<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20230831000934" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 8 月 31 日星期四 04:09:36 +0000</lastbuilddate><pubDate> Wed, 30 Aug 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>患有房颤的女性的中风风险</title><link/>https://pubmed.ncbi.nlm.nih.gov/37647629/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230831000934&amp;v=2.17.9.post6+86293ac<description>结论：年龄较大和心血管护理方面的不平等可能部分解释了患有 AF 的女性中风发生率较高的原因。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 30 日：ehad508。doi：10.1093/eurheartj/ehad508。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：在调整其他 CHA2DS2-VASc 因素后，女性与心房颤动 (AF) 中风的较高发生率相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：基于人群的队列研究，使用 2007 年至 2019 年间安大略省诊断为 AF 的 66 岁以上人群的管理数据集。使用特定原因风险回归来估计与女性相关的中风的调整后风险比 (HR)。 2 年随访。模型 1 包括 CHA2DS2-VASc 因素，年龄建模为 66-74 岁 vs. ≥ 75 岁。模型 2 将年龄视为连续变量，并包括年龄-性别交互项。模型 3 进一步解释了心血管护理的多发病率和标志物。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：该队列由 354 254 名 AF 患者组成（中位年龄 78 岁，49.2% 为女性）。女性在急诊科被诊断的可能性更大，接受心脏病专家评估、他汀类药物或 LDL-C 检测的可能性较小，女性的比例更高女性中的 LDL-C 水平高于男性。在模型 1 中，与女性相关的卒中校正 HR 为 1.27（95% 置信区间 1.21-1.32）。模型 2 显示了显着的年龄-性别交互作用，因此女性仅是与年龄 >; 70 岁的中风风险增加相关。调整心血管护理和多发病的标志物进一步降低了 HR，因此女性与年龄 ≤ 80 岁的中风风险增加无关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：年龄较大和心血管护理方面的不平等可能部分解释了患有 AF 的女性中风发生率较高的原因。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37647629/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37647629</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad508>10.1093/eurheartj/ehad508</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37647629</guid><pubDate> Wed, 30 Aug 2023 06:00:00 -0400</pubDate><dc:creator>希夫扎·布哈里</dc:creator><dc:creator>方吉明</dc:creator><dc:creator>鹿晗</dc:creator><dc:creator>Peter C Austin更多</dc:creator><dc:creator>保罗·多里安</dc:creator><dc:creator>辛西娅·杰克维修斯</dc:creator><dc:creator>于艾米</dc:creator><dc:creator>Moira K Kapral更多</dc:creator><dc:creator>谢尔顿·M·辛格</dc:creator><dc:creator>涂凯伦</dc:creator><dc:creator>高丹尼斯</dc:creator><dc:creator>克莱尔·L·阿泽玛</dc:creator><dc:creator>埃米莉亚·J·本杰明</dc:creator><dc:creator>道格拉斯·S·李</dc:creator><dc:creator>胡萨姆·阿卜杜勒·卡迪尔</dc:creator><dc:date>2023-08-30</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>患有房颤的女性的中风风险</dc:title><dc:identifier>下午：37647629</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad508</dc:identifier></item><item><title>动脉粥样硬化冠状动脉斑块消退和不良心血管事件的风险：系统回顾和更新的荟萃回归分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/37647074/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230831000934&amp;v=2.17.9.post6+86293ac<description>结论和相关性：在这项荟萃分析中，动脉粥样硬化斑块消退 1% 与 MACE 发生率降低 25% 相关。这些研究结果表明，PAV 的变化可以作为 MACE 的替代标志物，但考虑到 MACE 的异质性结果，需要额外的数据。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol.2023 年 8 月 30 日。doi：10.1001/jamacardio.2023.2731。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：降脂疗法 (LLT) 引起的动脉粥样硬化斑块变化与主要不良心血管事件 (MACE) 减少之间的关联仍存在争议。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估血管内超声（IVUS）评估的冠状动脉斑块消退与主要不良心血管事件（MACE）之间的关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">数据来源：对 PubMed、Embase、Cochrane Central Register of Controlled Trials 和 Web of Science 中的出版物进行了全面、系统的检索。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">研究选择：选择了 LLT 的临床前瞻性研究，报告了 IVUS 评估的动脉粥样硬化体积百分比 (PAV) 的变化并描述了 MACE 组成部分。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">数据提取和综合：按照系统评价和荟萃分析指南的首选报告项目进行报告。使用混合效应、2 级二项式逻辑回归模型通过元回归分析 PAV 和 MACE 平均变化之间的关联，未经调整和调整临床协变量，包括平均年龄、基线 PAV、基线低密度脂蛋白胆固醇水平和研究持续时间。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和指标：在更新的系统评价和 LLT IVUS 试验的荟萃回归分析中评估了干预组和比较组的平均 PAV 变化和 MACE，这些试验也报告了 MACE。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：这项荟萃分析包括 2001 年 7 月至 2022 年 7 月期间发表的 23 项研究，包括 7407 名患者，试验持续时间为 11 至 104 周。患者平均年龄 (SD) 为 55.8 (9.8) 至 70.2 (7.6) 岁，并且男性患者数量从 507 名患者中的 245 名 (48.3%) 增加到 26 名患者中的 24 名 (92.3%)。46 个研究组的 PAV 变化范围为 -5.6% 至 3.1%。每个研究组的 MACE 数量范围为 0 至 72 例（17 个组 [37%] 报告没有事件，9 个组 [20%] 报告 1-2 个事件，20 个 [43%] 报告 ≥ 3 个事件）。在未经调整的分析中，平均 PAV 下降 1% 与 17% 相关MACE 的几率降低（未调整 OR，0.83；95% CI，0.71-0.98；P = .03），调整分析中 MACE 降低 14%（调整 OR，0.86；95% CI，0.75-1.00；P = .050）。对心血管危险因素的进一步调整显示，PAV 每降低 1%，风险就会降低 19%（调整后 OR，0.81；95% CI，0.68–0.96；P = .01）。PAV 变化降低 1%研究中的干预组和比较组之间的 MACE 显着降低 25%（OR，0.75；95% CI，0.56–1.00；P = .046）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：在这项荟萃分析中，动脉粥样硬化斑块消退 1% 与 MACE 发生率降低 25% 相关。这些研究结果表明，PAV 的变化可以作为 MACE 的替代标志物，但考虑到 MACE 的异质性结果，需要额外的数据。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37647074/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37647074</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2731>10.1001/jamacardio.2023.2731</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37647074</guid><pubDate> Wed, 30 Aug 2023 06:00:00 -0400</pubDate><dc:creator>尤利亚·伊坦</dc:creator><dc:creator>关美娇</dc:creator><dc:creator>卡琳·H·汉弗莱斯</dc:creator><dc:creator>杨尤妮丝</dc:creator><dc:creator>英国约翰·曼奇尼</dc:creator><dc:date>2023-08-30</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>动脉粥样硬化冠状动脉斑块消退和不良心血管事件的风险：系统回顾和更新的荟萃回归分析</dc:title><dc:identifier>下午：37647074</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2731</dc:identifier></item><item><title>一名 70 多岁患有慢性稳定型心绞痛的男性患者在冠​​状动脉成形术中错误地快速交换球囊充气</title><link/>https://pubmed.ncbi.nlm.nih.gov/37647059/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230831000934&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol.2023 年 8 月 30 日。doi：10.1001/jamacardio.2023.2658。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37647059/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37647059</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2658>10.1001/jamacardio.2023.2658</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37647059</guid><pubDate> Wed, 30 Aug 2023 06:00:00 -0400</pubDate><dc:creator>希希尔·K·鲁尔</dc:creator><dc:creator>阿维纳什·阿尔克</dc:creator><dc:creator>绍拉布·阿吉特·德什潘德</dc:creator><dc:date>2023-08-30</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>一名 70 多岁患有慢性稳定型心绞痛的男性患者在冠​​状动脉成形术中错误地快速交换球囊充气</dc:title><dc:identifier>下午：37647059</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2658</dc:identifier></item><item><title>不良童年经历是心血管健康的社会决定因素</title><link/>https://pubmed.ncbi.nlm.nih.gov/37647054/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230831000934&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol.2023 年 8 月 30 日。doi：10.1001/jamacardio.2023.2678。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37647054/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37647054</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2678>10.1001/jamacardio.2023.2678</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37647054</guid><pubDate> Wed, 30 Aug 2023 06:00:00 -0400</pubDate><dc:creator> ——安-玛丽·纳瓦尔</dc:creator><dc:creator>萨迪亚·汗</dc:creator><dc:creator>克莱德·W·扬西</dc:creator><dc:date>2023-08-30</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>不良童年经历是心血管健康的社会决定因素</dc:title><dc:identifier>下午：37647054</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2678</dc:identifier></item><item><title>虚弱引导的心血管疾病管理——从临床试验到临床实践</title><link/>https://pubmed.ncbi.nlm.nih.gov/37647048/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230831000934&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol.2023 年 8 月 30 日。doi：10.1001/jamacardio.2023.1634。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37647048/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37647048</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.1634>10.1001/jamacardio.2023.1634</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37647048</guid><pubDate> Wed, 30 Aug 2023 06:00:00 -0400</pubDate><dc:creator>金大贤</dc:creator><dc:creator>钟莉莉</dc:creator><dc:creator>——迈克尔·W·里奇</dc:creator><dc:date>2023-08-30</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>虚弱引导的心血管疾病管理——从临床试验到临床实践</dc:title><dc:identifier>下午：37647048</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.1634</dc:identifier></item><item><title>修改 GRACE 风险评分以预测急性冠脉综合征患者的风险</title><link/>https://pubmed.ncbi.nlm.nih.gov/37647046/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230831000934&amp;v=2.17.9.post6+86293ac<description>结论和相关性：在本研究中，在 GRACE 风险评分中使用连续而非二元 hs-cTn T（心肌损伤程度的代表）可改善 ACS 患者的死亡风险预测。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol.2023 年 8 月 30 日。doi：10.1001/jamacardio.2023.2741。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：全球急性冠脉事件登记处 (GRACE) 风险评分是指南推荐的针对急性冠脉综合征 (ACS) 患者的风险分层工具，并未考虑心肌损伤的程度。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估改良 GRACE 评分在就诊时结合高敏心肌肌钙蛋白 (hs-cTn) T 的增量预测价值（心肌损伤程度的替代指标）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、背景和参与者：这项回顾性设计的纵向队列研究检查了2009年9月至2017年12月期间入组的3个独立队列，共9803名ACS患者；2个ACS衍生队列（海德堡ACS队列和纽卡斯尔STEMI队列）和一个ACS验证队列（SPUM）海德堡 ACS 队列包括 2535 名连续诊断为 ACS 的患者，SPUM-ACS 研究包括 4288 名连续患者。纽卡斯尔 STEMI 队列包括 2980 名连续接受直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者。分析时间为 3 月至 6 月。 2023 年。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">暴露：院内、30 天和 1 年死亡风险估计源自更新的风险评分，其中包含就诊时的连续 hs-cTn T（改良版 GRACE）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和指标：连续 hs-cTn T 和改良 GRACE 风险评分与原始 GRACE 风险评分相比的预测价值。研究终点是住院期间以及指标事件后 30 天和 1 年的全因死亡率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在纳入的 9450 名患者中，7313 名 (77.4%) 为男性，就诊时的平均 (SD) 年龄为 64.2 (12.6) 岁。与原始 GRACE 相比，使用连续而不是二元 hs-cTn T 可以改善区分和重新分类评分（院内死亡率：受试者工作特征曲线下面积 [AUC]，0.835 vs 0.741；连续净重分类改善 [NRI]，0.208；30 天死亡率：AUC，0.828 vs 0.740；NRI，0.312；1 年死亡率：衍生队列中的 AUC，0.785 vs 0.778；NRI，0.078。这些结果在验证队列中得到了证实。在 9450 名患者的汇总人群中，修改后的 GRACE 风险评分在以下方面表现出优于原始 GRACE 风险评分的表现：院内死亡率终点（AUC，0.878 vs 0.780；NRI，0.097）、30 天死亡率终点（AUC，0.858 vs 0.771；NRI，0.08）和 1 年死亡率终点（AUC，0.858 vs 0.771；NRI，0.08）的重新分类和区分的影响，0.813 与 0.797；NRI，0.056）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：在本研究中，在 GRACE 风险评分中使用连续而非二元 hs-cTn T（心肌损伤程度的代表）可改善 ACS 患者的死亡风险预测。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37647046/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37647046</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2741>10.1001/jamacardio.2023.2741</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37647046</guid><pubDate> Wed, 30 Aug 2023 06:00:00 -0400</pubDate><dc:creator>乔治斯·乔治普洛斯</dc:creator><dc:creator>西蒙·克拉勒</dc:creator><dc:creator>马蒂亚斯·米勒·亨尼森</dc:creator><dc:creator>迪米特里奥斯·德利亚利斯</dc:creator><dc:creator>乔治斯·马夫拉加尼斯</dc:creator><dc:creator>凯特琳娜·索波娃</dc:creator><dc:creator>弗洛里安·温兹尔</dc:creator><dc:creator>洛伦兹·拉贝尔</dc:creator><dc:creator>莫里茨·比纳</dc:creator><dc:creator>芭芭拉·E·斯塔利</dc:creator><dc:creator>埃莱妮·马内塔</dc:creator><dc:creator>卢克·斯普雷</dc:creator><dc:creator>胡安·伊格莱西亚斯</dc:creator><dc:creator>何塞·科埃略·利马</dc:creator><dc:creator>西蒙·图尔-查洛特</dc:creator><dc:creator>奥利维尔·穆勒</dc:creator><dc:creator>弗朗索瓦·马赫</dc:creator><dc:creator>——诺伯特·弗雷</dc:creator><dc:creator>丹尼尔·杜尔施密德</dc:creator><dc:creator>哈拉尔德·F·兰格</dc:creator><dc:creator>雨果·卡图斯更多</dc:creator><dc:creator>马可·罗菲</dc:creator><dc:creator>乔瓦尼·G·卡米奇</dc:creator><dc:creator>克里斯蒂安·穆勒</dc:creator><dc:creator>埃万杰洛斯·贾尼西斯</dc:creator><dc:creator>约金·斯皮里多普洛斯</dc:creator><dc:creator>托马斯·F·卢舍尔</dc:creator><dc:creator>康斯坦丁诺斯·斯特洛斯</dc:creator><dc:creator>基蒙·斯塔马特洛普洛斯</dc:creator><dc:date>2023-08-30</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>修改 GRACE 风险评分以预测急性冠脉综合征患者的风险</dc:title><dc:identifier>下午：37647046</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2741</dc:identifier></item><item><title>儿童期父母监禁与成人高血压和心血管风险</title><link/>https://pubmed.ncbi.nlm.nih.gov/37647038/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230831000934&amp;v=2.17.9.post6+86293ac<description>结论和相关性：在这项针对从青年期过渡到成年期的美国成年人的队列研究中，在童年时期经历过父母监禁的人中，观察到高血压和高危 hsCRP 的发病率有所增加，但其他心血管危险因素却没有增加。大规模监禁的后果。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol.2023 年 8 月 30 日。doi：10.1001/jamacardio.2023.2672。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：父母监禁是一种不利的童年经历，对少数种族个体影响尤为严重，并与长期健康风险相关。尽管心血管疾病仍然是美国黑人和白人之间死亡率差异的主要原因，但父母监禁之间的关联心血管风险仍然知之甚少。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：探讨儿童期父母监禁与成年期心血管事件风险之间的关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、背景和参与者：这项基于人群的队列研究包括美国国家青少年到成人健康纵向研究第四波（2008-2009年）和第五波（2016-2018年）的数据。参与者代表从青年期过渡的美国成年人至成年。数据分析时间为2021年10月28日至2023年5月1日。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和指标：父母监禁被定义为参与者年龄小于 18 岁时，父母或类似父母的人物入狱。结果指标包括自我报告的肥胖、高脂血症、高血压、糖尿病或心脏病诊断以及血清中非高密度脂蛋白胆固醇 (≥160 mg/dL) 和高敏 C 反应蛋白 (hsCRP >; 3 mg/L) 的升高，这是用于估计未来冠状动脉事件风险的炎症标志物。使用抽样权重，将每个结果的事件发展建模为父母监禁的函数，并根据参与者和社区层面的特征进行调整。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：这项研究包括 9629 名参与者，代表 16 077 108 名美国成年人。大约一半参与者是女性（5498 名[权重 50.3%]），大多数（5895 名[权重 71.4%]）是白人。参与者平均年龄为 37.8 岁（第 V 波中的 95% CI，37.5 至 38.0 岁）与第 IV 波中的 28.9 岁（95% CI，28.6 至 29.1 岁）相比。在第 V 波中，童年时期曾经历过父母监禁的人的受教育程度较低（91 [权重 8.2]） %] vs 245 [加权 4.2%] 完成高中教育以下），拥有较高的公共保险比例（257 [加权 20.6%] vs 806 [加权 11.0%]），并且黑人比例过高（374 [加权 22.5%] vs父母监禁与发生高血压的调整后赔率增加 33%（95% CI，1.05 至 1.68）相关，与发生 hsCRP 升高的调整后赔率增加 60%（95% CI，1.03 至 2.48）相关。儿童期父母监禁与其他诊断之间的关联未观察到肥胖、高脂血症、糖尿病或心脏病）和血清脂质水平。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：在这项针对从青年期过渡到成年期的美国成年人的队列研究中，在童年时期经历过父母监禁的人中，观察到高血压和高危 hsCRP 的发病率有所增加，但其他心血管危险因素却没有增加。大规模监禁的后果。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37647038/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37647038</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2672>10.1001/jamacardio.2023.2672</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37647038</guid><pubDate> Wed, 30 Aug 2023 06:00:00 -0400</pubDate><dc:creator>伊丽莎白·L·董</dc:creator><dc:creator>克里斯汀·E·弗罗布莱夫斯基</dc:creator><dc:creator>詹妮弗·马克拉斯基</dc:creator><dc:creator>——纳撒尼尔·J·格拉瑟</dc:creator><dc:creator>史黛西·泰斯勒·林道</dc:creator><dc:date>2023-08-30</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>儿童期父母监禁与成人高血压和心血管风险</dc:title><dc:identifier>下午：37647038</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2672</dc:identifier></item><item><title>讣告-Paul JE Erne教授</title><link/>https://pubmed.ncbi.nlm.nih.gov/37646640/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230831000934&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 30 日：ehad550。doi：10.1093/eurheartj/ehad550。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37646640/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37646640</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad550>10.1093/eurheartj/ehad550</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37646640</guid><pubDate> Wed, 30 Aug 2023 06:00:00 -0400</pubDate><dc:creator>托马斯·F·卢舍尔</dc:creator><dc:creator>汉斯·里克利</dc:creator><dc:creator>米歇尔·朱贝尔</dc:creator><dc:date>2023-08-30</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>讣告-Paul JE Erne教授</dc:title><dc:identifier>下午：37646640</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad550</dc:identifier></item><item><title>动脉粥样硬化蛋白质组图谱：蛋白多糖对性别差异、斑块表型和结果的贡献</title><link/>https://pubmed.ncbi.nlm.nih.gov/37646165/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230831000934&amp;v=2.17.9.post6+86293ac<description>结论：斑块蛋白质组学重新定义了具有不同结果的临床相关患者群体，确定了未来心血管事件风险升高的男性和女性患者亚组。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 30 日。doi：10.1161/CIRCRESAHA.123.322590。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：利用蛋白质组学，我们的目标是揭示人类动脉粥样硬化病变的分子类型，并研究它们与组织学、影像学和心血管结果的关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：从 120 名患者身上采集了 219 份颈动脉内膜切除术样本。采用序贯蛋白质提取方案与多重发现蛋白质组学相结合。为了关注细胞外蛋白质，采用平行反应监测进行靶向蛋白质组学。蛋白质组学特征与本体整合、单细胞和空间 RNA 测序数据，并在 Athero-Express Biobank 研究的 200 名患者中进行了验证。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：这项广泛的蛋白质组学分析确定了斑块炎症和钙化特征，这些特征与靶向蛋白质组学、胎球蛋白-A、骨桥蛋白和γ-羧化蛋白呈负相关并得到验证。蛋白质组学数据还揭示了动脉粥样硬化中存在大聚集蛋白聚糖的性别差异。多功能蛋白聚糖和聚集蛋白聚糖在女性中更为丰富，并与雌二醇水平呈负相关。数据将炎症特征主要归因于中性粒细胞和巨噬细胞，将钙化和性别特征归因于平滑肌细胞，但某些不表达但保留的血浆蛋白除外斑块中，如胎球蛋白-A。根据蛋白质组学数据识别 4 种不同的斑块表型。4 种关键蛋白质（钙调蛋白、蛋白质 C、丝氨酸蛋白酶抑制剂 H1 和多功能蛋白聚糖）的蛋白质特征预测未来心血管死亡率，曲线下面积为在发现和验证队列中分别为 75% 和 67.5%，超过了影像学和组织学的预后表现。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：斑块蛋白质组学重新定义了具有不同结果的临床相关患者群体，确定了未来心血管事件风险升高的男性和女性患者亚组。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37646165/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37646165</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322590>10.1161/CIRCRESAHA.123.322590</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37646165</guid><pubDate> Wed, 30 Aug 2023 06:00:00 -0400</pubDate><dc:creator>康斯坦丁诺斯·塞奥菲拉托斯</dc:creator><dc:creator>斯特凡·斯托伊科维奇</dc:creator><dc:creator>玛丽亚·哈斯曼</dc:creator><dc:creator>桑德·W·范德兰</dc:creator><dc:creator>费欣·拜格</dc:creator><dc:creator>哈维尔·巴拉洛布雷·巴雷罗</dc:creator><dc:creator>卢卡斯·施密特</dc:creator><dc:creator>尹思琪</dc:creator><dc:creator>尹晓科</dc:creator><dc:creator>肖恩·伯纳普</dc:creator><dc:creator>巴瓦纳·辛格</dc:creator><dc:creator>裘德·波帕姆</dc:creator><dc:creator>奥莱西亚·哈科特</dc:creator><dc:creator>斯蒂芬妮·坎普夫</dc:creator><dc:creator>玛雅·卡琳娜·纳肯霍斯特</dc:creator><dc:creator>安德烈亚斯·斯特拉斯尔</dc:creator><dc:creator>克里斯蒂安·罗意威</dc:creator><dc:creator>斯维特拉娜·德米亚涅茨</dc:creator><dc:creator>克里斯托夫·纽迈尔</dc:creator><dc:creator>马丁·比尔班</dc:creator><dc:creator>克里斯蒂安·亨斯滕伯格</dc:creator><dc:creator>库尔特·胡贝尔</dc:creator><dc:creator>杰拉德·帕斯特坎普</dc:creator><dc:creator>约翰·沃伊塔</dc:creator><dc:creator>曼努埃尔·迈尔</dc:creator><dc:date>2023-08-30</dc:date><dc:source>流通研究</dc:source><dc:title>动脉粥样硬化蛋白质组图谱：蛋白多糖对性别差异、斑块表型和结果的贡献</dc:title><dc:identifier>下午：37646165</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322590</dc:identifier></item><item><title>健康信息收集、共享和使用原则：美国心脏协会的政策声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37646159/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230831000934&amp;v=2.17.9.post6+86293ac<description>电子健康记录的发展，加上数据管理和分析技术的进步，越来越多地实现了数据共享和协调。健康相关和健康代理信息分析的进步已经加速了研究发现并改善了患者护理。心脏协会政策声明讨论了广泛的数据共享如何通过提供数据来开发、测试和基准测试来推动进步...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 30 日。doi：10.1161/CIR.0000000000001173。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">电子健康记录的发展，加上数据管理和分析技术的进步，越来越多地实现了数据共享和协调。健康相关和健康代理信息分析的进步已经加速了研究发现并改善了患者护理。心脏协会政策声明讨论了广泛的数据共享如何通过提供数据来开发、测试和基准测试创新方法、可扩展的见解以及数据存储和工作流程的潜在新范式，从而成为进步的推动力。一些健康数据的敏感性，关于公平性的考虑历史上被排除在外的社区的参与，以及试图管理行为的复杂的法律交叉。因此，数据共享原则对于广泛的实体是必要的，包括收集健康信息的各方、资助者。本政策声明概述了一些关键的公平和原则与健康数据共享和负责任的管理相关的法律背景。然后阐明了指导美国心脏协会参与与数据收集、共享和使用相关的公共政策的原则，以继续为其整个研究企业的工作提供信息，以及具体的建议如何在政策环境中应用这些原则的示例：以尊重患者和研究参与者的方式使用或重复使用健康信息，在风险和潜在利益方面具有公平的影响，并有益于广泛和人口多样化美国的社区。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37646159/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37646159</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001173>10.1161/CIR.0000000000001173</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37646159</guid><pubDate> Wed, 30 Aug 2023 06:00:00 -0400</pubDate><dc:creator>凯特·斯佩克特-巴格达迪</dc:creator><dc:creator>安东尼斯·阿蒙达斯</dc:creator><dc:creator>里玛·阿诺特</dc:creator><dc:creator>詹妮弗·L·霍尔</dc:creator><dc:creator>布鲁克·耶格尔·麦克斯温</dc:creator><dc:creator>约书亚·W·诺尔斯</dc:creator><dc:creator>W·尼克尔森·普莱斯</dc:creator><dc:creator>丹达·拉瓦特</dc:creator><dc:creator>芭芭拉·里格尔</dc:creator><dc:creator>王翠西</dc:creator><dc:creator>——凯文·威利</dc:creator><dc:creator>钟米娜</dc:creator><dc:creator>美国心脏协会倡导协调委员会</dc:creator><dc:date>2023-08-30</dc:date><dc:source>循环</dc:source><dc:title>健康信息收集、共享和使用原则：美国心脏协会的政策声明</dc:title><dc:identifier>下午：37646159</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001173</dc:identifier></item><item><title> SIRT3 通过去乙酰化 Frataxin 调节凋亡心肌细胞的清除</title><link/>https://pubmed.ncbi.nlm.nih.gov/37646156/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230831000934&amp;v=2.17.9.post6+86293ac<description>结论：SIRT3-FXN 轴具有通过增加巨噬细胞胞吞作用和抗炎活性来解决心脏炎症的潜力。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 30 日。doi：10.1161/CIRCRESAHA.123.323160。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：胞吞作用是巨噬细胞的一种活性，对于高血压炎症的解决至关重要。巨噬细胞协调胞吞作用和内化凋亡心肌细胞的确切机制仍不清楚。本研究的目的是确定 SIRT3 (sirtuin-3) 是否细胞凋亡过程中凋亡心肌细胞吞噬和抗炎反应所必需的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们制备了髓系 SIRT3 敲除小鼠和携带乙酰化缺陷型赖氨酸至精氨酸 K189R 突变（FXN <sup>K189R</sup> ）的敲入小鼠。给小鼠注射 Ang II（血管紧张素 II）7 天。我们分析了心脏巨噬细胞的线粒体铁。体内和体外的水平、胞吞活性和表型。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们发现 SIRT3 缺乏加剧了 Ang II 诱导的胞吞作用受体 MerTK（c-Mer 酪氨酸激酶）的下调和促炎细胞因子的产生，并伴随着心脏巨噬细胞中线粒体铁稳态的破坏。定量乙酰组分析显示，SIRT3 去乙酰化 FXN（frataxin） ) 在赖氨酸 189 处。Ang II 减弱 SIRT3 活性并增强 FXN K189 的乙酰化水平。乙酰化 FXN 进一步减少 ISC（铁硫簇）的合成，导致线粒体铁积累。凋亡心肌细胞的吞噬内化增加了肌红蛋白含量，并且衍生的铁离子促进线粒体铁超载和脂质过氧化。铁螯合剂去铁胺提高了 MerTK 和胞吞作用的水平，从而减弱了促炎巨噬细胞的活化。FXN <sup>K189R</sup>小鼠表现出改善的巨噬细胞胞吞作用，减少了心脏炎症，并抑制了心脏纤维化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：SIRT3-FXN 轴具有通过增加巨噬细胞胞吞作用和抗炎活性来解决心脏炎症的潜力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37646156/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37646156</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323160>10.1161/CIRCRESAHA.123.323160</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37646156</guid><pubDate> Wed, 30 Aug 2023 06:00:00 -0400</pubDate><dc:creator>高靖</dc:creator><dc:creator>黄成林</dc:creator><dc:creator>孔令辉</dc:creator><dc:creator>周武刚</dc:creator><dc:creator>孙孟伟</dc:creator><dc:creator>童薇</dc:creator><dc:creator>沉伟丽</dc:creator><dc:date>2023-08-30</dc:date><dc:source>流通研究</dc:source><dc:title>SIRT3 通过去乙酰化 Frataxin 调节凋亡心肌细胞的清除</dc:title><dc:identifier>下午：37646156</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323160</dc:identifier></item><item><title>昼夜节律医学：心脏护理的关键策略</title><link/>https://pubmed.ncbi.nlm.nih.gov/37644115/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230831000934&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol.2023 年 8 月 29 日。doi：10.1038/s41569-023-00925-8。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37644115/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37644115</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00925-8>10.1038/s41569-023-00925-8</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37644115</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator> ——迈克尔·J·索尔</dc:creator><dc:creator>塔米·马蒂诺</dc:creator><dc:date>2023-08-29</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>昼夜节律医学：心脏护理的关键策略</dc:title><dc:identifier>下午：37644115</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00925-8</dc:identifier></item><item><title>非甾体盐皮质激素受体拮抗剂治疗心力衰竭</title><link/>https://pubmed.ncbi.nlm.nih.gov/37644114/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230831000934&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 8 月 29 日。doi：10.1038/s41569-023-00922-x。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37644114/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37644114</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00922-x>10.1038/s41569-023-00922-x</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37644114</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>格拉西莫斯·菲利帕托斯</dc:creator><dc:creator>迪米特里奥斯·法马基斯</dc:creator><dc:date>2023-08-29</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>非甾体盐皮质激素受体拮抗剂治疗心力衰竭</dc:title><dc:identifier>下午：37644114</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00922-x</dc:identifier></item><item><title> DDM1 对组蛋白 H3 变体的染色质重塑是 DNA 甲基化表观遗传的基础</title><link/>https://pubmed.ncbi.nlm.nih.gov/37643610/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230831000934&amp;v=2.17.9.post6+86293ac<description>核小体会阻止 DNA 甲基转移酶的进入，除非它们通过 DNA 甲基化 1 的减少 (DDM1^(LSH)^(^(/)HELLS)) 进行重塑，这是一种表观遗传遗传的类似 Snf2 的主调节因子。我们表明，DDM1 促进H3.1 产生组蛋白变体 H3.3。在 ddm1 突变体中，DNA 甲基化因 H3.3 伴侣 HIRA 的丢失而部分恢复，而 H3.1 伴侣 CAF-1 变得至关重要。单颗粒冷冻电镜结构3.2 Å 的 DDM1 与变异核小体揭示了...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 24 日：S0092-8674(23)00855-3. doi: 10.1016/j.cell.2023.08.001. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">核小体会阻止 DNA 甲基转移酶的进入，除非它们通过 DNA 甲基化 1 的减少 (DDM1 <sup>LSH</sup> <sup><sup>/</sup> HELLS</sup> ) 进行重塑，DNA 甲基化 1 是表观遗传的 Snf2 样主调节因子。我们表明，DDM1 促进组蛋白变体 H3.3 被 H3.1 取代在 ddm1 突变体中，DNA 甲基化因 H3.3 伴侣蛋白 HIRA 的丢失而部分恢复，而 H3.1 伴侣蛋白 CAF-1 变得至关重要。DDM1 3.2 Å 处的单颗粒冷冻电镜结构与变异核小体揭示了接合组蛋白 H3.3 靠近组装所需的残基以及未修饰的 H4 尾。N 端自抑制结构域抑制活性，而解旋酶结构域中的二硫键支持活性。DDM1 在组装过程中与 H3.1 和 H3.3 共定位细胞周期，以及 DNA 甲基转移酶 MET1 <sup>Dnmt1</sup> ，但被 H4K16 乙酰化阻断。雄性种系 H3.3 变体 MGH3/HTR10 对 DDM1 的重塑具有抵抗力，并充当精子细胞中表观遗传的占位核小体。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37643610/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37643610</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.001>10.1016/j.cell.2023.08.001</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37643610</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>李承祖</dc:creator><dc:creator>德克斯特·W·亚当斯</dc:creator><dc:creator>乔纳森·J·伊普萨罗</dc:creator><dc:creator>——乔纳森·卡恩</dc:creator><dc:creator>贾森·林恩</dc:creator><dc:creator>金贤秀</dc:creator><dc:creator>本杰明·贝鲁贝</dc:creator><dc:creator>维多利亚·梅杰</dc:creator><dc:creator>约瑟夫·P·卡拉科</dc:creator><dc:creator>尚塔尔·勒布朗</dc:creator><dc:creator>索娜莉·巴塔查吉</dc:creator><dc:creator>乌玛玛赫斯瓦里·拉穆</dc:creator><dc:creator>丹尼尔·格里马内利</dc:creator><dc:creator>雅尼克·雅各布</dc:creator><dc:creator>菲利普·沃伊特</dc:creator><dc:creator>利莫尔·约书亚·托尔</dc:creator><dc:creator>罗伯特·马丁森</dc:creator><dc:date>2023-08-29</dc:date><dc:source>细胞</dc:source><dc:title>Chromatin remodeling of histone H3 variants by DDM1 underlies epigenetic inheritance of DNA methylation</dc:title><dc:identifier> pmid:37643610</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.001</dc:identifier></item><item><title> Initiating Mineralocorticoid Antagonists for Longstanding Heart Failure With Reduced Ejection Fraction: Better Late Than Never?</title><link/> https://pubmed.ncbi.nlm.nih.gov/37642609/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831000934&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Aug 1:S0735-1097(23)06074-6. doi: 10.1016/j.jacc.2023.06.022. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37642609/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37642609</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.06.022>10.1016/j.jacc.2023.06.022</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37642609</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Andrew J Sauer</dc:creator><dc:creator> Judith Hsia</dc:creator><dc:date> 2023-08-29</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Initiating Mineralocorticoid Antagonists for Longstanding Heart Failure With Reduced Ejection Fraction: Better Late Than Never?</dc:title><dc:identifier> pmid:37642609</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.022</dc:identifier></item><item><title> Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction</title><link/> https://pubmed.ncbi.nlm.nih.gov/37642608/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831000934&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Patients with longer-standing HFrEF had worse clinical status and a higher rate of events, but the benefit of eplerenone was consistent regardless of HFrEF duration. (A Comparison of Outcomes in Patients in NYHA Class II Heart Failure When Treated With Eplerenone or Placebo in Addition to Standard Heart Failure Medicines [EMPHASIS-HF]; NCT00232180). </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Aug 1:S0735-1097(23)06073-4. doi: 10.1016/j.jacc.2023.06.021. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: It is unknown how the efficacy and safety of mineralocorticoid receptor antagonists vary according to duration of heart failure with reduced ejection fraction (HFrEF). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: In this study, we sought to evaluate the safety and efficacy of eplerenone according to duration of HFrEF. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: In the EMPHASIS-HF trial, 3 patient groups were created according to HFrEF duration: &lt;1 year, 1 to &lt;5 years, and ≥5 years. The primary outcome was the composite of heart failure (HF) hospitalization or cardiovascular death. Outcomes were adjusted for prespecified prognostic variables and examined with the use of Cox regression models. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: The numbers of patients in each group were: 975, &lt;1 year; 769, 1 to &lt;5 years; and 988, ≥5 years. Patients with longer-standing HF were older and more frequently had cardiovascular and noncardiovascular comorbidities. The rate of the primary outcome (per 100 person-years) increased with HFrEF duration: 9.8 (95% CI: 8.4-11.4) for &lt;1 year, 13.5 (95% CI: 11.6-15.7) for 1 to &lt;5 years, and 17.6 (95% CI: 15.6-19.8) for ≥5 years. The benefits of eplerenone were consistent across HF duration: HRs for the primary outcome were 0.57 (95% CI: 0.42-0.79) for &lt;1 year, 0.81 (95% CI: 0.60-1.10) for 1 to &lt;5 years, and 0.61 (95% CI: 0.48-0.78) for ≥5 years; P <sub>interaction</sub> = 0.24. The absolute benefit was greatest in the longest-duration group: the number needed to treat for the primary outcome was 14 for &lt;1 year, 13 for 1 to &lt;5 years, and 10 for ≥5 years duration. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Patients with longer-standing HFrEF had worse clinical status and a higher rate of events, but the benefit of eplerenone was consistent regardless of HFrEF duration. (A Comparison of Outcomes in Patients in NYHA Class II Heart Failure When Treated With Eplerenone or Placebo in Addition to Standard Heart Failure Medicines [EMPHASIS-HF]; NCT00232180).</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37642608/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37642608</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.06.021>10.1016/j.jacc.2023.06.021</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37642608</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Shingo Matsumoto</dc:creator><dc:creator> Toru Kondo</dc:creator><dc:creator> Pardeep S Jhund</dc:creator><dc:creator> Ross T Campbell</dc:creator><dc:creator> Karl Swedberg</dc:creator><dc:creator> Dirk J van Veldhuisen</dc:creator><dc:creator> Stuart J Pocock</dc:creator><dc:creator> Bertram Pitt</dc:creator><dc:creator> Faiez Zannad</dc:creator><dc:creator> John JV McMurray</dc:creator><dc:date> 2023-08-29</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction</dc:title><dc:identifier> pmid:37642608</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.021</dc:identifier></item><item><title> The ESC Working Group on cardiovascular regenerative and reparative medicine</title><link/> https://pubmed.ncbi.nlm.nih.gov/37642557/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831000934&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 29:ehad538. doi: 10.1093/eurheartj/ehad538. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37642557/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37642557</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad538>10.1093/eurheartj/ehad538</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37642557</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Giulio Pompilio</dc:creator><dc:creator> Ricardo Sanz-Ruiz</dc:creator><dc:creator> Joost PG Sluijter</dc:creator><dc:creator> Stefan Janssens</dc:creator><dc:date> 2023-08-29</dc:date><dc:source> European heart journal</dc:source><dc:title> The ESC Working Group on cardiovascular regenerative and reparative medicine</dc:title><dc:identifier> pmid:37642557</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad538</dc:identifier></item><item><title> Incorporating principles from commercial advertising into cardiovascular health promotion efforts</title><link/> https://pubmed.ncbi.nlm.nih.gov/37642214/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831000934&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 29:ehad537. doi: 10.1093/eurheartj/ehad537. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37642214/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37642214</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad537>10.1093/eurheartj/ehad537</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37642214</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator> David JT Campbell</dc:creator><dc:creator> Raj Pannu</dc:creator><dc:creator> Braden J Manns</dc:creator><dc:date> 2023-08-29</dc:date><dc:source> European heart journal</dc:source><dc:title> Incorporating principles from commercial advertising into cardiovascular health promotion efforts</dc:title><dc:identifier> pmid:37642214</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad537</dc:identifier></item><item><title> S14-Phosphorylated RPN6 Mediates Proteasome Activation by PKA and Alleviates Proteinopathy</title><link/> https://pubmed.ncbi.nlm.nih.gov/37641975/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831000934&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: This study establishes in animals that pS14-Rpn6 mediates the activation of 26S proteasomes by PKA and that the reduced pS14-Rpn6 is a key pathogenic factor in cardiac proteinopathy, thereby identifying a new therapeutic target to reduce cardiac proteotoxicity. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 Aug 29. doi: 10.1161/CIRCRESAHA.123.322887. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: A better understanding of the regulation of proteasome activities can facilitate the search for new therapeutic strategies. A cell culture study shows that cAMP-dependent PKA (protein kinase A) activates the 26S proteasome by pS14-Rpn6 (serine14-phosphorylated Rpn6), but this discovery and its physiological significance remain to be established in vivo. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Male and female mice with Ser14 of Rpn6 mutated to Ala (S14A [Rpn6/Psmd11 <sup>S14A</sup> ]) or Asp (S14D) to respectively block or mimic pS14-Rpn6 were created and used along with cells derived from them. cAMP/PKA were manipulated pharmacologically. Ubiquitin-proteasome system functioning was evaluated with the GFPdgn reporter mouse and proteasomal activity assays. Impact of S14A and S14D on proteotoxicity was tested in mice and cardiomyocytes overexpressing the misfolded protein R120G-CryAB (R120G). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: PKA activation increased pS14-Rpn6 and 26S proteasome activities in wild-type but not S14A embryonic fibroblasts (mouse embryonic fibroblasts), adult cardiomyocytes, and mouse hearts. Basal 26S proteasome activities were significantly greater in S14D myocardium and adult mouse cardiomyocytes than in wild-type counterparts. S14D::GFPdgn mice displayed significantly lower myocardial GFPdgn protein but not mRNA levels than GFPdgn mice. In R120G mice, a classic model of cardiac proteotoxicity, basal myocardial pS14-Rpn6 was significantly lower compared with nontransgenic littermates, which was not always associated with reduction of other phosphorylated PKA substrates. Cultured S14D neonatal cardiomyocytes displayed significantly faster proteasomal degradation of R120G than wild-type neonatal cardiomyocytes. Compared with R120G mice, S14D/S14D::R120G mice showed significantly greater myocardial proteasome activities, lower levels of total and K48-linked ubiquitin conjugates, and of aberrant CryAB protein aggregates, less fetal gene reactivation, and cardiac hypertrophy, and delays in cardiac malfunction. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: This study establishes in animals that pS14-Rpn6 mediates the activation of 26S proteasomes by PKA and that the reduced pS14-Rpn6 is a key pathogenic factor in cardiac proteinopathy, thereby identifying a new therapeutic target to reduce cardiac proteotoxicity.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37641975/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37641975</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.123.322887>10.1161/CIRCRESAHA.123.322887</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37641975</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Liuqing Yang</dc:creator><dc:creator> Nirmal Parajuli</dc:creator><dc:creator> Penglong Wu</dc:creator><dc:creator> Jinbao Liu</dc:creator><dc:creator> Xuejun Wang</dc:creator><dc:date> 2023-08-29</dc:date><dc:source> Circulation research</dc:source><dc:title> S14-Phosphorylated RPN6 Mediates Proteasome Activation by PKA and Alleviates Proteinopathy</dc:title><dc:identifier> pmid:37641975</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322887</dc:identifier></item><item><title> Rare Variant Genetics and Dilated Cardiomyopathy Severity: The DCM Precision Medicine Study</title><link/> https://pubmed.ncbi.nlm.nih.gov/37641966/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831000934&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Advanced DCM was associated with higher odds of rare variants in DCM genes adjudicated as pathogenic or likely pathogenic, compared with individuals with less severe DCM. This finding may help assess the risk of outcomes in management of patients with DCM and their at-risk family members. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Aug 29. doi: 10.1161/CIRCULATIONAHA.123.064847. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Dilated cardiomyopathy (DCM) can lead to advanced disease, defined herein as necessitating a durable left ventricular assist device or a heart transplant (LVAD/HT). DCM is known to have a genetic basis, but the association of rare variant genetics with advanced DCM has not been studied. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We analyzed clinical and genetic sequence data from patients enrolled between 2016 and 2021 in the US multisite DCM Precision Medicine Study, which was a geographically diverse, multiracial, multiethnic cohort. Clinical evaluation included standardized patient interview and medical record query forms. DCM severity was classified into 3 groups: patients with advanced disease with LVAD/HT; patients with an implantable cardioverter defibrillator (ICD) only; or patients with no ICD or LVAD/HT. Rare variants in 36 DCM genes were classified as pathogenic or likely pathogenic or variants of uncertain significance. Confounding factors we considered included demographic characteristics, lifestyle factors, access to care, DCM duration, and comorbidities. Crude and adjusted associations between DCM severity and rare variant genetic findings were assessed using multinomial models with generalized logit link. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Patients&#39; mean (SD) age was 51.9 (13.6) years; 42% were of African ancestry, 56% were of European ancestry, and 44% were female. Of 1198 patients, 347 had LVAD/HT, 511 had an ICD, and 340 had no LVAD/HT or ICD. The percentage of patients with pathogenic or likely pathogenic variants was 26.2%, 15.9%, and 15.0% for those with LVAD/HT, ICD only, or neither, respectively. After controlling for sociodemographic characteristics and comorbidities, patients with DCM with LVAD/HT were more likely than those without LVAD/HT or ICD to have DCM-related pathogenic or likely pathogenic rare variants (odds ratio, 2.3 [95% CI, 1.5-3.6]). The association did not differ by ancestry. Rare variant genetic findings were similar between patients with DCM with an ICD and those without LVAD/HT or ICD. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Advanced DCM was associated with higher odds of rare variants in DCM genes adjudicated as pathogenic or likely pathogenic, compared with individuals with less severe DCM. This finding may help assess the risk of outcomes in management of patients with DCM and their at-risk family members. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> REGISTRATION: URL: https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CLINICALTRIALS: gov; Unique identifier: NCT03037632.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37641966/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37641966</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064847>10.1161/CIRCULATIONAHA.123.064847</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37641966</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Mark Hofmeyer</dc:creator><dc:creator> Garrie J Haas</dc:creator><dc:creator> Elizabeth Jordan</dc:creator><dc:creator> Jinwen Cao</dc:creator><dc:creator> Evan Kransdorf</dc:creator><dc:creator> Gregory A Ewald</dc:creator><dc:creator> Alanna A Morris</dc:creator><dc:creator> Anjali Owens</dc:creator><dc:creator> Brian Lowes</dc:creator><dc:creator> Douglas Stoller</dc:creator><dc:creator> WH Wilson Tang</dc:creator><dc:creator> Sonia Garg</dc:creator><dc:creator> Barry H Trachtenberg</dc:creator><dc:creator> Palak Shah</dc:creator><dc:creator> Salpy V Pamboukian</dc:creator><dc:creator> Nancy K Sweitzer</dc:creator><dc:creator> Matthew T Wheeler</dc:creator><dc:creator> Jane E Wilcox</dc:creator><dc:creator> Stuart Katz</dc:creator><dc:creator> Stephen Pan</dc:creator><dc:creator> Javier Jimenez</dc:creator><dc:creator> Frank Smart</dc:creator><dc:creator> Jessica Wang</dc:creator><dc:creator> Stephen S Gottlieb</dc:creator><dc:creator> Daniel P Judge</dc:creator><dc:creator> Charles K Moore</dc:creator><dc:creator> Gordon S Huggins</dc:creator><dc:creator> Daniel D Kinnamon</dc:creator><dc:creator> Hanyu Ni</dc:creator><dc:creator> Ray E Hershberger</dc:creator><dc:creator> DCM Precision Medicine Study of the DCM Consortium</dc:creator><dc:date> 2023-08-29</dc:date><dc:source> Circulation</dc:source><dc:title> Rare Variant Genetics and Dilated Cardiomyopathy Severity: The DCM Precision Medicine Study</dc:title><dc:identifier> pmid:37641966</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.064847</dc:identifier></item><item><title> Cardiac Vagal Nerve Activity Increases During Exercise to Enhance Coronary Blood Flow</title><link/> https://pubmed.ncbi.nlm.nih.gov/37641938/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230831000934&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Our study demonstrates that cardiac vagal nerve activity actually increases and is crucial for maintaining cardiac function during exercise. Furthermore, our findings show the dynamic modulation of coronary artery blood flow during exercise is mediated by VIP. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 Aug 29. doi: 10.1161/CIRCRESAHA.123.323017. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: The phrase complete vagal withdrawal is often used when discussing autonomic control of the heart during exercise. However, more recent studies have challenged this assumption. We hypothesized that cardiac vagal activity increases during exercise and maintains cardiac function via transmitters other than acetylcholine. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Chronic direct recordings of cardiac vagal nerve activity, cardiac output, coronary artery blood flow, and heart rate were recorded in conscious adult sheep during whole-body treadmill exercise. Cardiac innervation of the left cardiac vagal branch was confirmed with lipophilic tracer dyes (DiO). Sheep were exercised with pharmacological blockers of acetylcholine (atropine, 250 mg), VIP (vasoactive intestinal peptide; [4Cl-D-Phe6,Leu17]VIP 25 µg), or saline control, randomized on different days. In a subset of sheep, the left cardiac vagal branch was denervated. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Neural innervation from the cardiac vagal branch is seen at major cardiac ganglionic plexi, and within the fat pads associated with the coronary arteries. Directly recorded cardiac vagal nerve activity increased during exercise. Left cardiac vagal branch denervation attenuated the maximum changes in coronary artery blood flow (maximum exercise, control: 63.5±5.9 mL/min, n=8; cardiac vagal denervated: 32.7±5.6 mL/min, n=6, <i>P=</i> 2.5×10 <sup>-</sup> <sup>7</sup> ), cardiac output, and heart rate during exercise. Atropine did not affect any cardiac parameters during exercise, but VIP antagonism significantly reduced coronary artery blood flow during exercise to a similar level to vagal denervation. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Our study demonstrates that cardiac vagal nerve activity actually increases and is crucial for maintaining cardiac function during exercise. Furthermore, our findings show the dynamic modulation of coronary artery blood flow during exercise is mediated by VIP.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37641938/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230831000934&v=2.17.9.post6+86293ac">37641938</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.123.323017>10.1161/CIRCRESAHA.123.323017</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37641938</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Julia Shanks</dc:creator><dc:creator> Mridula Pachen</dc:creator><dc:creator> Joshua WH Chang</dc:creator><dc:creator> Bindu George</dc:creator><dc:creator> Rohit Ramchandra</dc:creator><dc:date> 2023-08-29</dc:date><dc:source> Circulation research</dc:source><dc:title> Cardiac Vagal Nerve Activity Increases During Exercise to Enhance Coronary Blood Flow</dc:title><dc:identifier> pmid:37641938</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323017</dc:identifier></item></channel></rss>